Physician
Jabr, Ayman
Jabr, Ayman was paid $4.34M by Medicaid between Jan 2018 and Dec 2024, across 73 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 32% of everything it billed.
33Billing provider infoJABR, AYMAN
CHICAGO, IL 60622
CHICAGO, IL 60622
33aNPI1669582417assigned 08/30/2006
33bProvider typeFamily Medicine Physician
28Total paid$4.34M
24GClaims106,177
24DCodes billed73
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Illinois
Rank by total paid#15 of 2,947
Median peer was paid$43K
This provider vs. median102×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,524 | $99K | |
| 2019 | 10,529 | $207K | |
| 2020 | 13,149 | $306K | |
| 2021 | 15,914 | $623K | |
| 2022 | 20,487 | $925K | |
| 2023 | 23,431 | $1.18M | |
| 2024incomplete | 18,143 | $1.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32% | 20,846 | 15,552 | $1.38M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 25% | 3,227 | 2,879 | $1.08M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.2% | 6,271 | 5,172 | $311K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.9% | 3,251 | 2,937 | $254K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 3.5% | 6,443 | 2,144 | $150K |
| 87581 | 3.3% | 3,374 | 3,016 | $145K | |
| 87486 | 3.3% | 3,371 | 3,013 | $144K | |
| 99222 | Initial hospital care, per day, moderate complexity | 2.6% | 2,624 | 2,307 | $114K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.4% | 3,108 | 2,646 | $106K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.4% | 11,531 | 5,832 | $105K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.1% | 2,125 | 1,955 | $90K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.0% | 1,783 | 1,613 | $87K |
61 more codes
| 99308 | Subsequent nursing facility care, per day, straightforward | 1.1% | 3,631 | $48K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,579 | $36K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,368 | $36K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,482 | $35K |
| 90686 | <1% | 1,083 | $20K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 297 | $19K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,788 | $12K |
| 99253 | <1% | 230 | $10K | |
| 99384 | <1% | 95 | $10K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 169 | $9K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 103 | $9K |
| 82962 | <1% | 4,397 | $8K | |
| 20610 | <1% | 250 | $8K | |
| 99385 | <1% | 86 | $7K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 298 | $7K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 90 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,628 | $6K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,157 | $6K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 474 | $6K |
| 99401 | <1% | 177 | $5K | |
| 90674 | <1% | 238 | $5K | |
| 99383 | <1% | 50 | $5K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 17 | $4K |
| 0013A | <1% | 108 | $4K | |
| 0011A | <1% | 99 | $4K | |
| 0012A | <1% | 80 | $3K | |
| 81003 | <1% | 1,582 | $3K | |
| 90688 | <1% | 219 | $3K | |
| 96127 | <1% | 263 | $3K | |
| 86328 | <1% | 59 | $3K | |
| 99421 | <1% | 210 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 317 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 26 | $2K |
| 99386 | <1% | 19 | $2K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 21 | $2K |
| 93000 | <1% | 76 | $1K | |
| 94760 | <1% | 573 | $1K | |
| 99223 | Prolong inpt eval add15 m | <1% | 54 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 30 | $1K |
| 99173 | <1% | 140 | $1K | |
| 81025 | <1% | 210 | $1K | |
| 99305 | <1% | 33 | $836.04 | |
| 91322 | <1% | 17 | $540.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 798 | $499.12 |
| 96136 | <1% | 18 | $488.70 | |
| 90714 | <1% | 19 | $464.43 | |
| 86580 | <1% | 80 | $456.71 | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 23 | $429.98 |
| 99441 | <1% | 142 | $417.88 | |
| 90480 | <1% | 14 | $407.39 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $401.60 |
| G0008 | Administration of influenza virus vaccine | <1% | 43 | $376.82 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 23 | $359.95 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 760 | $319.50 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 139 | $187.62 |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,014 | $132.06 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 92 | $128.53 |
| 99072 | <1% | 139 | $50.00 | |
| 99406 | <1% | 13 | $37.50 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 51 | $35.82 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 20 | $2.50 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.